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Background: In the current acute kidney injury (AKI) definition, the urine output (UO) criterion does not specify
which body weights (BW), i.e. actual (ABW) versus ideal (IBW), should be used to diagnose and stage AKI, leading to
heterogeneity across research studies.
Methods: This is a single center, retrospective, observational study conducted at a tertiary referral hospital. All adult
patients who were admitted to intensive care units (ICUs) at our institution for a minimum of 6 continuous hours
between January and March 2010 and had a urinary catheter for hourly urine output monitoring were eligible for
this study. Patients’ AKI stages, based on UO criterion, were assessed by calculating each milliliter of urine per
kilogram per hour, using ABW versus IBW.
Results: A total of 493 ICU patients were included in the analysis. The median ABW and IBW were 82 (IQR 68-96)
and 70 (IQR 60-77) kg, respectively. Using the IBW criterion, 154 patients (31.2%) were diagnosed with AKI, while
204 (41.4%) were diagnosed using the ABW measurement (P-value < .01). Patients who had AKI regardless of BW
type had an adjusted odds ratio of 1.76 (95% CI 1.05-2.95) for 90-day mortality, whereas patients who had AKI
according to ABW but not IBW had no significant increase in the risk of 90-day mortality, adjusted OR 0.76;
(95% CI 0.25-1.91), compared to patients who had no AKI.
Conclusions: Using ABW to diagnose and stage AKI by UO criterion is more sensitive and less specific than IBW.
Based on the application of the definition, different BW types could be utilized.
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Acute kidney injury (AKI) is a frequent clinical syn-
drome among hospitalized, and particularly in critically
ill, patients. The incidence of AKI occurring in patients
admitted to intensive care units (ICUs) ranges from 30-
60% [1]. Independently associated with both short and
long-term mortality [2-4], AKI-associated mortality was
reported to be as high as 23% [5].
Previously, there have been many different definitions
of AKI used in the literature and clinical practice. Vari-
ous classifications, RIFLE (Risk, Injury, Failure, Loss of
function, and End-stage renal disease [ESRD]) criteria in* Correspondence: thongprayoon.charat@mayo.edu
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article, unless otherwise stated.2004, AKIN (Acute Kidney Injury Network) criteria in
2007, and most recently, KDIGO (Kidney Disease Im-
proving Global Outcomes) criteria in 2012, have been
developed and validated to standardize the diagnosis and
staging the severity of AKI [6-8]. The definition of AKI
is currently based on absolute or relative changes in
serum creatinine (SCr) and weight-adjusted hourly urine
output (UO), respectively (Table 1). A general consensus
of these definitions has reduced the variation in AKI re-
search studies findings, as the vast majority of investiga-
tions within the past decade used these similar definitions
to diagnose and stage AKI.
Studies have found oliguria can be an early indicator
of kidney dysfunction and is independently associated
with poor mortality and morbidity [9,10]. Body weight
(BW) is an important factor and used when normalizingCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 KDIGO criterion for diagnosis and staging of
AKI [8]
Stage Serum creatinine Urine output
1 1.5-1.9 times baseline OR 0.3 mg/dl
increase
< 0.5 ml/kg/h for 6-12 hours
2 2.0-2.9 times baseline < 0.5 ml/kg/h for
≥12 hours
3 3.0 times baseline OR Increase in
serum creatinine to ≥4.0 mg/dl OR
initiation of replacement therapy
< 0.3 ml/kg/h for
≥24 hours OR Anuria for
≥12 hours
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currently normalized to BW may need to be adjusted to
an ideal body weight (IBW) to account for obesity or
cachexia. However, It is not clearly specified whether ac-
tual body weight (ABW) or IBW, should be used to de-
fine AKI. Although a large number of recent studies
reported UO criterion, the majority of them do not spe-
cify which body weight was used, leading to heterogen-
eity among different studies [8,11,12]. In this report, we
showed using different methods of measuring or calcu-
lating body weight can impact the sensitivity and specifi-
city of the AKI definition.
This study aims to (1) evaluate and compare the inci-
dence of AKI and its staging according to UO criteria,
using ABW versus IBW and (2) investigate how using
different BW calculations would affect predictive per-
formance of AKI on 90-day mortality and other morbid-
ities in critically ill patients.
Methods
Subjects and methods
This was a single-center retrospective study conducted
at a tertiary referral hospital. We studied all adult pa-
tients (age ≥18 years) admitted to an intensive care unit
(ICU) in our hospital (Mayo Clinic Hospital – Rochester,
Rochester, MN) for a minimum of six continuous hours
from January to February 2010. We excluded patients
without indwelling urinary catheters, patients with a his-
tory of ESRD, patients who received any dialysis modal-
ities within 14 days prior to the ICU admission, and
patients who did not provide research authorization.
This study was approved by the Mayo Clinic Institution
Review Board with a waiver of patient consent because
of retrospective and non-interventional fashion of this
study.
AKI diagnosis and staging
In the electronic medical record (EMR), AKI was diag-
nosed and staged based solely on the UO criterion of
the KDIGO definition (Table 1) [13]. Hourly UO data in
the ICU EMR was manually reviewed by a trained crit-
ical care physician (AA), blinded to patients’ vital status.
Patient weight is measured and recorded on daily basis,using digital weighting scale. Height is also measured by
measurement tape, at least one time at ICU admission.
The documented BW (in kg) on the first day of ICU ad-
mission was used as the ABW. The IBW was calculated
using the following equations [14]:
Males : IBW kgð Þ ¼ 50 kg þ 2:3 kg 
height inchð Þ−60½ 
Females : IBW kgð Þ ¼ 45:5 kg þ 2:3 kg 
height inchð Þ−60½ 
For patients who had an ABW greater than 1.3 times
their IBW, the IBW was further adjusted using the follo-
wing formula [15]:
Adjusted IBW ¼ IBW þ 0:4  ABW – IBW½ 
Based on the above calculations, the initial reviewer de-
termined a disagreement of AKI stages in 86 patients. The
EMRs of these 86 patients were subsequently reviewed by
a second physician (CT) who was blinded to the result of
the first reviewer. Disagreements of AKI stages between
the two reviewers were adjudicated by a joint review be-
tween these two physicians.
In a sensitivity analysis, we used both SCr and UO def-
initions for diagnosis and staging of AKI (Table 1). AKI
stage was assigned according to the highest stage using
either the SCr or UO criterion. The baseline SCr was de-
fined as the mean value of all SCr values measured
within 1 year before hospital admission. In 38 (7.7%)
patients whose measured SCr was not available, the
baseline SCr was estimated by the Modification of Diet
in Renal Disease (MDRD) equation, assuming baseline
estimated glomerular filtration rate (eGFR) of 75 ml/min
per 1.73 m2 [16].
Clinical outcomes
The primary outcome was 90-day mortality following the
index ICU admission. Vital statistics were first obtained by
reviewing the patients’ registration and EMRs to identify
patients’ mortality status beyond 90 days after ICU admis-
sion. In patients whose vital status at 90 days after ICU ad-
mission was unknown, due to lack of follow-up (4.8%), the
Social Security Death Index was used [17].
Statistical analysis
All continuous variables were reported as medians with
interquartile ranges (IQR). All categorical variables were
reported as counts with percentages. In the event of
missing information, data were not muted. For patients
with multiple ICU admissions, only the first ICU admis-
sion during the study period was included in analysis.
The difference in the ABW- versus IBW-based AKI diag-
nosis was assessed using a McNemar’s test. The difference
Table 2 Clinical characteristics and outcomes of critically
ill patients admitted in ICU during the study period
Characteristics Total (n = 493)
Age, year, median (IQR) 67 (54-77)
Male sex, n (%) 264 (54)
White, n (%) 440 (89)
BMI, kg/m2, median (IQR) 28 (24-33)
Body weight, kg, median (IQR)
- Actual body weight 82 (68-96)
- Ideal body weight 70 (60-77)
Baseline creatinine, mg/dL, median (IQR) 1 (0.8-1.2)
Comorbidities
- DM 115 (23)
- Coronary artery disease 59 (12)
- Stroke 49 (10)
- Congestive heart failure 34 (7)
- Chronic pulmonary disease 119 (24)
- Cirrhosis 27 (5)
- Chronic kidney disease*, n (%) 148 (30)
ICU type
- Medical ICU 216 (44)
- Surgical ICU 173 (35)
- Mixed ICU 104 (21)
APACHE III score, median (IQR) 44 (32-59)
SOFA score, median (IQR) 4 (2-7)
ICU length of stay, hour, median (IQR) 28 (20-55)
90-day mortality, n (%) 79 (16)
*Chronic kidney disease was defined by K/DOQI CKD stage III or worse (estimated
glomerular filtration rate <60 ml/min/1.73 m2 according to MDRD formula).
Abbreviation: APACHE Acute Physiology and Chronic Health Evaluation, SOFA
Sequential Organ Failure Assessment, BMI body mass index.
Table 3 AKI diagnoses and staging using UO criterion
with ABW and IBW
AKI stage
(Actual BW)
AKI stage (ideal BW) Total
N (%)0 1 2 3
0 289 (58.6) 0 (0) 0 (0) 0 (0) 289 (58.6)
1 45 (9.1) 61 (12.4) 0 (0) 0 (0) 106 (21.5)
2 5 (1.0) 31 (6.3) 40 (8.1) 0 (0) 76 (15.4)
3 0 (0) 0 (0) 5 (1.0) 17 (3.4) 22 (4.5)
Total, N (%) 339 (68.8) 92 (18.7) 45 (9.1) 17 (3.4) 493
Kappa = 0.78 (95% CI 0.73-0.84) and percentage agreement = 89.9% for
AKI diagnosis.
Kappa = 0.77 (95% CI 0.73-0.82) and percentage agreement = 82.6% for
AKI staging.
Abbreviation: AKI acute kidney injury, BW body weight, CI confidence interval.
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assessed using a paired t test. The agreement of AKI diag-
nosis and staging based on ABW and IBW was assessed
using Cohen’s weighted kappa coefficient with linear
weight between AKI stages. We adjusted odd ratios (ORs)
for pre-specified variables including, age and APACHE III
score, to assess 90-day mortality among patients who met
the UO criterion, regardless of type of BW measured, and
those who met UO criterion only (according to either
ABW or IBW but not the other) compared to non-AKI
patients. The association between AKI stages and 90-day
mortality was assessed using a logistic regression analysis.
The predictive performance of the UO criterion, using dif-
ferent BW calculations, for 90-day mortality was assessed
by c-statistics; after which we compared their perfor-
mances using Delong’s test. A two-sided P value of < .05
was considered statistically significant. Sensitivity and spe-
cificity of ABW-based and IBW-based AKI diagnosis were
calculated using serum creatinine-based definition as the
reference. All analyses were performed using JMP statis-
tical software (version 9.0, SAS, Cary, NC).
Results
During the study period, 639 critically ill patients were
admitted to ICU. Of these, 146 were excluded: 31 had
ESRD or received dialysis within 14 days prior to ICU
admission, 101 had no indwelling urinary catheter for
hourly UO monitoring, and 14 had an ICU length of
stay of <6 hours. A total of 493 patients were analyzed.
The clinical characteristics of these patients at the ICU
admissions and their outcomes are summarized in Table 2.
The median age was 67 years (IQR 54-77); 54% were men
and 30% had chronic kidney disease. The median body
mass index (BMI) was 28 kg/m2 (IQR 24-33). The median
ABW and IBW were 82 (IQR 68-96) and 70 (IQR 60-77)
kg respectively (p <0.001).
AKI diagnosis and staging using ABW and IBW
When patients’ ABW measurements were used, AKI was
diagnosed in 204 (41.4%) of the patients, with 21.5% in
stage 1, 15.4% in stage 2 and 4.5% in stage 3. Using
IBW, AKI occurred in 154 (31.2%) patients with 18.7%
in stage 1, 9.1% in stage 2 and 3.4% in stage 3. Accordingly,
using ABW could identify more AKI cases than IBW
(P < .001) (Table 3).
The percentage agreement for AKI diagnosis, using
the two different body weight assertation methods, was
89.9% with a kappa of 0.78 (95% CI, 0.73-0.84). Results
show that ABW and IBW both agreed in 154 AKI cases
and 289 non-AKI cases. Using a different BW measure-
ment resulted in a discrepancy in AKI diagnosis in 50
cases (10.1%). All of these 50 patients had AKI according
to ABW but not IBW. The number of patients who had
AKI with IBW but not with ABW was zero. The
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kappa of 0.77 (95% CI, 0.73-0.82).Time-to-AKI diagnosis using ABW and IBW
We found that in patients who were diagnosed with AKI,
regardless of body weight methodology. Using ABW de-
tected AKI significantly earlier than using IBW with the
mean difference in time-to-diagnosis of 4.0 hours (95% CI,
0.2-7.7; P = .04). The ABW method was able to identify
AKI earlier than IBW in 20.1% of these patients, whereas
79.2% had AKI at the same time, according to both types
of BW.Risk for 90-day mortality
Of these patients, 16% (n = 79) died within 90 days after
their ICU admission. The 90-day mortality rates after
ICU admission for AKI stages by ABW and IBW are
shown in Figure 1. With ABW, there was a statistically
non-significant trend toward a higher 90-mortality rate
in AKI cases compared to non-AKI cases (19.6% vs.
13.5%; P = .06). In contrast, with IBW, the 90-day mor-
tality rate was significantly higher in AKI cases com-
pared to non-AKI cases (22.7% vs. 13.0%; P = .006).
Compared to patients who did not have AKI, patients
who had AKI, regardless of the BW calculation, had an
adjusted OR for 90-day mortality of 1.76 (95% CI, 1.05-
2.95), whereas patients who had AKI according to ABW
but not by IBW had non-significant increase in 90-day
mortality risk (adjusted OR = 0.76; 95% CI, 0.25-1.91)
(Table 4). Calculating the performance for the prediction
of 90-day mortality, the C-statistic for ABW and IBW
methods were 0.58 and 0.60, respectively. C-statistics
were not statistically different between the two methods
(P = .37).Figure 1 90-day mortality rate according to AKI stages (UO definitionSensitivity analysis
When both SCr and UO criteria were used for AKI diag-
nosis and staging, similarly, using ABW could detect more
AKI cases (50.5% vs. 42.4%; P < .001) (see Additional file 1:
Table S1, Table S2, Table S3, Figure S1). In term of out-
come prediction, compared to non-AKI cases, the morta-
lity was significantly higher in AKI cases defined by ABW
(19.3% vs. 12.7%; P = .04) as well as by IBW (21.1% vs.
12.3%; P = .01) in comparison with non-AKI patients.
There was no significant difference in c-statistic for 90-day
mortality discrimination between ABW and IBW (0.60 vs.
0.59, P = .33).
Using SCr criteria as reference standard for AKI diag-
nosis, the sensitivity of ABW-based and IBW-based AKI
diagnosis were 64.8% and 57.0% respectively (P = .002).
The specificity of ABW-based and IBW-based AKI diag-
nosis were 66.4% and 77.6% respectively (P < .001). The
positive predictive values for ABW-based and IBW-
based AKI diagnosis were 41.5% and 48.3% respectively
(P = .20). The negative predictive value for ABW-based
and IBW-based AKI diagnosis were 83.7% and 83.1% re-
spectively (P = .84).
Discussion
We conducted a large retrospective cohort study to exam-
ine the effect of using different body weight methods,
ABW and IBW, on epidemiology and prognostication per-
formance of AKI definition. This study showed that using
ABW for AKI diagnosis not only can identify more pa-
tients with AKI but also identifies these cases earlier. Al-
though, specificity may decrease due to false positive
cases, as some AKI cases had a similar prognosis as non-
AKI cases. Normalization of UO with different body
weight will significantly affect the incidence of AKI in
ICUs, leading to heterogeneity among different studies.).
Table 4 90-day mortality risk
Actual BW Ideal
BW
N 90-mortality rate Adjusted OR
(95% CI)*
AKI AKI 154 22.7% 1.76 (1.05-2.95)
AKI No AKI 50 10% 0.76 (0.25-1.91)
No AKI AKI 0 n/a n/a
No AKI No AKI 289 13.5% Reference
*OR is adjusted for age and APACHE score.
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be clearly stated as the UO criterion is defined for both
AKI diagnosis and classification.
Up to two-thirds of patients in the ICU are reported
as having AKI [18]. Even a modest degree of renal
insufficiency in the ICU is associated with increased in-
hospital mortality [19,20]. Prevention and early diagno-
sis of AKI are the keys to minimizing further insults.
While awaiting for the ongoing investigations for novel
biomarkers for the early AKI detection [21], using ABW
for the UO criterion will provide better sensitivity and
earlier time-to-AKI diagnosis in clinical practice in
order to promptly detect AKI and prevent further kidney
damage.
Recently, there have been studies proposing that the
current UO definition may be too liberal and may over-
diagnose AKI in critically ill patients [11,12]. With the
current definition, using IBW makes the AKI definition
more specific. Most of patients who were diagnosed
with AKI, according to ABW but not according to IBW,
had temporary borderline oliguria and the outcome of
patients in this group was similar to patients without
AKI.
A counterintuitive finding in this study was that the
90-day mortality rate among patients who had AKI ac-
cording to ABW but not IBW was statistically non-
significant lower than patients who had no AKI (10% vs
13.5%; p = 0.50). One possible explanation for the ob-
served trend, is obesity paradox phenomenon as the
median BMI of the first group was significantly higher
than of the latter group [32 (IQR 29-35) vs 27 (23-32)
kg/m2; P < .001]. A few epidemiological studies have re-
cently reported improved outcomes in obese patients in
ICU when compared with those with normal weight
[22]. Druml et. al. studied the impact of body mass on
incidence and prognosis of AKI in the ICU and demon-
strated a greater survival benefit after AKI requiring renal
replacement therapy in obese patients compared to under-
weight or normal weight patients [23]. When we added
BMI into the 90-day mortality prediction model, it showed
a trend toward increased adjusted OR of 90-day mortality
from 0.76 (0.25-1.91) to 0.95 (0.30-2.42).
The choice of using ABW or IBW for AKI diagnosis
and classification depends on the purpose of the AKIdefinition. In clinical practice, AKI prevention and early
treatment may improve patient outcomes. Therefore, for
screening purposes in clinical practice, we support the
use of ABW to normalize UO for AKI diagnosis, as it
can potentially identify more AKI cases earlier. On the
other hand, for research studies that enroll patients with
AKI for invasive medical intervention, using IBW may
be more appropriate, as it is likely to select patients who
are going to benefit the intervention.
Our study has some limitations. This report is a retro-
spective study and inherently subjective to biases of a
retrospective study. The other potential limitation is the
small number of underweight patients admitted to our
ICU. In the majority of our patients ABW was more
than their IBW. This made it difficult to generalize our
study findings to patient populations with a lower BMI.
In our cohort, 38 patients had a BMI of ≤20 kg/m2.
Among these underweight patients, AKI was diagnosed
in 10 (26.3%) using ABW and in 9 (23.7%) using IBW
(P = .32). This suggests that the need for BW adjustment
for AKI diagnosis when using UO criterion might not be
necessary in patients with a low BMI. However, further
studies are needed to confirm the diagnostic and pre-
dictive abilities of different BW calculation for under-
weight patients. Second, we did not have information
regarding fluid balance as the fluid administration before
ICU admission may affect the actual BW measured at
ICU admission. However, we selected the first body
weight measured in ICU to minimize the impact of fluid
balance on actual body weight.
Yet, with these limitations our study carries some
strength as well. It is a large cohort of patients in medical
and surgical ICUs with different critical illnesses. We were
able to access hourly UOt in this large sample. In addition,
this is the only report that focuses on the type of BW for
normalization of UO criterion on AKI definition.
Conclusions
In summary, using ABW for UO criterion increases its
sensitivity and allows earlier diagnosis of AKI; however
it does not add to the prediction performance of the
AKI definition for 90-day mortality when compared with
IBW. Based on our data, we suggest ABW to be called
“sensitivity BW” for risk stratification purposes, whereas
IBW should be called “specificity BW” for enrollment in
more invasive diagnostic and therapeutic measures.Additional file
Additional file 1: Table S1. Baseline characteristics of ICU patients
grouped by the occurrence of AKI using ABW and IBW for diagnosis.
Table S2. AKI diagnoses and staging according to SCr and UO definition
using actual and ideal BW. Table S3. 90-day mortality risk. Figure S1. 90-day
mortality rate according to AKI stages (SCr and UO definition).
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